Illumina Launches HumanOmniExpress BeadChip
The company claims that OmniExpress designed as a 12-sample Beadchip, allows interrogation of over 700,000 variants per sample totaling more than eight million available data points on a
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
The Phase 2a study has demonstrated proof-of-concept for DR Cysteamine, which is Raptor’s proprietary, delayed-release, enteric-coated microbead formulation of immediate release cysteamine bitartrate contained in a gelatin capsule.